Promising response to neoadjuvant pembrolizumab and low-dose chemotherapy in advanced endometrial cancer: A preliminary report
Neoadjuvant pembrolizumab with low-dose chemotherapy demonstrated promising efficacy and acceptable safety in advanced EC, with favorable outcomes in high-grade malignancies regardless of molecular subtype. These findings warrant further investigation in selected patients.
Authors
- Lai Chyong-Huey
- You-Chen Wang
- Chen-Bin Chang
- Yen-Ling Huang (ORCID: https://orcid.org/0000-0003-2699-8350)
- Chien-Chi Lu
- Ting-Chang Chang
- Angel Chao
- Shih-Ming Jung
Institutions
- Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jfma.2026.02.003
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 41.10